<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200415047097N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-08</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect of low-level laser therapy on muscle performance of young adults</public_title>
      <acronym></acronym>
      <scientific_title>Effect of low-level laser therapy on muscle performance of young adults</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-04-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47250</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: To minimize the risk of selection bias, block randomization was performed. The participants, according to their Body Mass Index or BMI, were divided into two subgroups of BMI less than 25 (22 participants) and BMI equal to 25 or more (28 participants). Randomization was carried out in each subgroup separately, with a block size of 4. 2 cards of A and 2 cards of B were shuffled and randomly put together and the operator of the randomization, according to the order that the cards were arranged, assigned the participants to groups A or B. The participant who had received card A, was placed in group A and received a real laser, whereas the participant who had received card B, was placed in group B and received a placebo. All of the randomization steps were carried out by the trial operators. The participants and the operators of randomization didn't know to which group A and B cards belong, Blinding description: To avoid performance bias, double-blinding was done; meaning that the participants didn’t know whether they were in the real laser or the placebo group and the laser therapy operator was unable to differentiate between active and placebo laser. The laser device was programmed by a nurse who was not in contact with the participants. Then a second operator who was blinded to the allocation of the subjects applied the phototherapy. The signals and sounds of the device in on and off mode were completely similar and the operator couldn’t differentiate whether it is on or off. So, both participants and operators were blinded to the type of treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Rehabilitation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The participants settled in group A due to the block randomization and in the second session, before the exercise, receive one session of the real laser at 810 nm wavelength, 60mW power, and 60Hz frequency for 30 seconds on 3 points of rectus femoris muscle, 30 seconds on each point. (Laser device brand MPTC, model LMPT2000, made in Iran). To find the points, the distance between the Anterior Superior Iliac Spine (ASIS) to the upper border of the patella was divided into 3 equal regions and the middle point of every region was considered as an irradiation point. Intervention 2: Control group: The participants settled in group B due to the block randomization and in the second session, before the exercise, received the placebo laser (with probe off) on 3 points of rectus femoris muscle, 30 seconds on each point. (Laser device brand MPTC, model LMPT2000, made in Iran).  To find the points, the distance between the Anterior Superior Iliac Spine (ASIS) to the upper border of the patella was divided into 3 equal regions and the middle point of every region was considered as an irradiation point.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Using the data is allowed after the participants are non-recognizable

When:
Beginning the data access 6 months after the results are published

To whom:
All researchers in university associations

Conditions:
Data analysis is allowed for use in meta-analyses and clinical review studies

Where to obtain:
for accessing the data please send an e-mail to the address h.anahita64@yahoo.com Dr. Nina Hazegh. Name and the telephone number, the association, posting address, e-mail of the person who has requested for the data is necessary.

How to obtain:
after receiving the request and recognizing the identity of the person who has sent the request, the data will be sent in a week

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nina Hazegh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No7., Masud deadend, Golestan deadend, Jeishir St., 3rd Moshtagh St.</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8158161543</zip>
        <telephone>098 31 32634143</telephone>
        <email>h.anahita64@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nina Hazegh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 7 masud dead end, Golestan avenue, Sarvestan street, Jeishir street, 3rd Moshtagh street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8158161543</zip>
        <telephone>+98 31 3263 4143</telephone>
        <email>h.anahita64@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age in the range of 20-35
Being sedentary (no history of regular exercise during the past 3 months)
No history of professional sport during the lifetime</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>35 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any musculoskeletal disorder prohibiting the use of a treadmill or weight
Consuming any drug or supplements
Previous history of injury to Quadriceps femoris or Hamstring muscles</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The participants settled in group A due to the block randomization and in the second session, before the exercise, receive one session of the real laser at 810 nm wavelength, 60mW power, and 60Hz frequency for 30 seconds on 3 points of rectus femoris muscle, 30 seconds on each point. (Laser device brand MPTC, model LMPT2000, made in Iran). To find the points, the distance between the Anterior Superior Iliac Spine (ASIS) to the upper border of the patella was divided into 3 equal regions and the middle point of every region was considered as an irradiation point.</i_keyword>
      <i_keyword>Control group: The participants settled in group B due to the block randomization and in the second session, before the exercise, received the placebo laser (with probe off) on 3 points of rectus femoris muscle, 30 seconds on each point. (Laser device brand MPTC, model LMPT2000, made in Iran).  To find the points, the distance between the Anterior Superior Iliac Spine (ASIS) to the upper border of the patella was divided into 3 equal regions and the middle point of every region was considered as an irradiation point.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Level of the blood lactate. Timepoint: At the beginning of the study 3 days before the intervention and in the second session 20 minutes after the intervention. Method of measurement: Lactometer brand ECF (made in Italy) and brand Sensal No 74 lactometer kit (made in China), using a fingertip blood sample. The blood sample was collected by puncturing the fingertip using a lancet brand Ava (made in Iran).</prim_outcome>
      <prim_outcome>Number of knee extensions with a 10 kg weight. Timepoint: At the beginning of the study 3 days before the intervention and in the second session 5 minutes after the intervention. Method of measurement: Counting the number of complete knee extensions.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fatigue. Timepoint: At the beginning of the study 3 days before the intervention and 20 minutes after the intervention in the second session. Method of measurement: Scoring subjectively by the RPE (Rating of Perceived Exertion) scale, from 6 (minimum fatigue) to 20 (exhaustion).</sec_outcome>
      <sec_outcome>Muscle soreness. Timepoint: 2 days before the intervention (24 hours after the first session exercise) and 24 hours after the intervention. Method of measurement: Scoring subjectively from 1 (the least pain) to 10 (the maximum pain).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-17</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Third floor, Medicine faculty, Kudakyar St., Shahid Shahriary Sq., Shahid Chamran highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
